Home
Loading

aVenture is in Alpha: During this preview period, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to provide early access to our data to showcase the product as we build, but you should not yet rely upon it alone for your investment decisions.

aVenture is in Alpha: During this preview period, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to provide early access to our data to showcase the product as we build, but you should not yet rely upon it alone for your investment decisions.

Get in touch

  • Contact

  • Request a demo

  • Request data updates

  • Add a company

Research

  • Companies

  • Investors

  • People

aVenture

  • Sitemap

  • Feature requests

Member

Backed by

© aVenture Investment Company, 2026. All rights reserved.

San Francisco, CA, USA

Privacy Policy

aVenture Investment Company ("aVenture") is an independent research platform providing detailed analysis and data on startups, venture capital investments, and key industry individuals. It is not a registered investment adviser, broker-dealer, or investment advisor and does not provide investment advice or recommendations. The data provided by aVenture does not constitute recommendations or advice, whether by methodology, analysis, AI-generated content, or a statement written by a staff member of aVenture.

aVenture is not affiliated with any of the people, companies, organizations, government agencies, regulatory bodies, or investment funds we provide coverage for on this site unless explicitly stated otherwise. Users assume full responsibility for decisions made based on information obtained from this platform. Links to external websites do not imply endorsement or affiliation with aVenture. Any links that provide the ability to invest in a primary or secondary transaction in a company are for convenience only and do not constitute solicitations or offers to buy or sell an investment. Investors should exercise heightened precaution and due diligence when investing in private companies, especially those not independently audited.

While we strive to provide valuable insights with objectivity and professional diligence, we cannot guarantee the accuracy of the information provided on our platform. Before making any investment decisions, you should verify the accuracy of all pertinent details for your decision. To the fullest extent permitted by law, aVenture shall not be liable for any direct, indirect, incidental, consequential, or financial damages arising from use of this site, whether by consumers of its contents directly or by persons or organizations covered by our research, even if we are advised of the possibility. Our best-efforts processes and correction request forms do not create a warranty or duty of care.

Profiles on this platform may include content generated in part by large language models (LLMs, artificial intelligence) that aggregate publicly available sources (e.g., SEC EDGAR, public filings, press releases). Source attribution is provided where known; always verify statements and claims here against original sources before relying on any data. Content on our site may contain inaccuracies, omissions, or what are commonly called 'hallucinations' if generated in part or in full by AI / LLMs. The risk can also exist even when content is written by a human, as internal and third-party sources may also have inaccuracies for the same or different reasons. While we randomly audit a proportion of content, this is not exhaustive.

We recommend that an independent auditor be hired to verify the accuracy of the information before relying on it for any sensitive decisions. By accessing this platform, you agree not to rely solely on any information generated by AI, aggregated, or sourced or written otherwise on this site, for investment, financial, or other decisions. aVenture assumes no responsibility for inaccuracies, omissions, or hallucinations. You must independently verify all data from primary sources. Use of this platform constitutes your waiver of claims for reliance-based damages, including negligent misrepresentation. To report an error, request a correction, or dispute information about a company or individual, contact us via our request data updates form.

Loading homepage
Loading
Loading
Home›
Research›
People›
Christopher de Souza
AddedMar 31, 2024
UpdatedMay 31, 2026
Christopher de Souza

Christopher de Souza

Board Member, Ventrinova

Crunchbase

Christopher de Souza's Career

Ventrinova
Ventrinova

New York City, NY, US

Board Member· Board
Pulmokine
Pulmokine

Rensselaer, NY, US

Board Member· Board
DecImmune Therapeutics
DecImmune Therapeutics

Cambridge, MA, US

Board Member· Board
Mellitus
Mellitus

Boston, MA, US

Board Member· Board

Create your profile now and gain access to exclusive deals and high-potential startups.

aVenture product preview
aVenture product preview
aVenture product preview

Christopher de Souza's Career

Ventrinova
Ventrinova
Seed$1M52006New York City, NY, US
Board Member· Board

Similar to Ventrinova

Endogena TherapeuticsEndogena TherapeuticsSan Francisco, CA, USRegenerative Medicinesest. 2016Endogena TherapeuticsSan Francisco, CA, US · est. 2016

Endogena, a biotech firm, pioneers in developing first-in-class regenerative medicines for tissue and organ repair.

Series A · $29M15
BioventrixBioventrixSan Ramon, CA, USMedical Devicesest. 2003BioventrixSan Ramon, CA, US · est. 2003

US-based BioVentrix, Inc. provides innovative medical devices for ischemic cardiomyopathy treatment globally.

Series A · $230.2M36
CardiovateCardiovateSan Antonio, TX, USMedical Devicesest. 2012CardiovateSan Antonio, TX, US · est. 2012

Cardiovate: A med-tech company focusing on tissue regeneration and repair in healthcare.

Seed · $1.1M5
Novoron BioscienceNovoron BioscienceSan Diego, CA, USPharmaceutical Therapiesest. 2014Novoron BioscienceSan Diego, CA, US · est. 2014

Biotech firm specializing in pharmaceutical therapies for central nervous system regeneration.

Seed · $13.8M5
Pulmokine
Pulmokine
Pre-Seed$1M752007Rensselaer, NY, US
Board Member· Board

Leadership at Pulmokine

Larry ZismanLarry ZismanFounder
DecImmune Therapeutics
DecImmune Therapeutics
Seed$8.4M72001Cambridge, MA, US
Board Member· Board

Leadership at DecImmune Therapeutics

Michael CarrollMichael CarrollFounder

Similar to DecImmune Therapeutics

Deciduous TherapeuticsDeciduous TherapeuticsSan Francisco, CA, USTherapeuticsest. 2018Deciduous TherapeuticsSan Francisco, CA, US · est. 2018

Deciduous Therapeutics: Innovating immune-modulatory therapies to remove senescent cells, improving health-span and treating age-related diseases.

Seed · $16.5M37
ImmuneSensor TherapeuticsImmuneSensor TherapeuticsDallas, TX, USBiotechnology, Therapeuticsest. 2019ImmuneSensor TherapeuticsDallas, TX, US · est. 2019

ImmuneSensor Therapeutics: A biotech firm innovating novel medicinal solutions.

Series A · $26.1M11
Mellitus
Mellitus
Series B$13.8M112011Boston, MA, US
Board Member· Board

Leadership at Mellitus

Joyce LonerganJoyce LonerganCo-Founder
John TagliamonteJohn TagliamonteCEO
Michael ChorevMichael ChorevBoard Member
Ellie McGuireEllie McGuireBoard Member
Jose HalperinJose HalperinCo-Founder
Steven YeciesSteven YeciesBoard Member

Similar to Mellitus

DiabetomicsDiabetomicsHillsboro, OR, USDiabetes Testsest. 2008DiabetomicsHillsboro, OR, US · est. 2008

DiabetOmics: Non-invasive diabetes management through comprehensive finger-prick blood analyses.

Public · $12.1M11

Christopher de Souza's Similar Executives & Operators

Jay Geoffrey WacherJay Geoffrey WacherBoard Member · BukalapakSoemantri BrodjonegoroSoemantri BrodjonegoroBoard Member · BukalapakLau Eng BoonLau Eng BoonBoard Member · BukalapakWILL WEI CHENGWILL WEI CHENGBoard Member · DiDiDhirubhai H. AmbaniDhirubhai H. AmbaniBoard Member · Reliance RetailMason YeoMason YeoBoard Member · KakaoJaeHong ChoiJaeHong ChoiBoard Member · KakaoYun SeokYun SeokBoard Member · Kakao

People Similar to Christopher de Souza

Scott NolanScott NolanPartner · Founders FundSteve JurvetsonSteve JurvetsonBoard Member · Glycos BiotechnologiesBrian SingermanBrian SingermanBoard Member · AffirmDrew GrahamDrew GrahamBoard Member · KBI BiopharmaDavid Allen JonesDavid Allen JonesBoard Member · Confluent HealthChris OnanChris OnanBoard Member · FoodMaven